menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Changing Treatment Paradigms in Type 1 Diabetes:  Role of Anti-CD3 Targeted Therapy -

Screening for Islet Autoantibodies in Children and Adolescents to Prevent/Delay T1D

close
0.50 credits
30 minutes
Changing Treatment Paradigms in Type 1 Diabetes:  Role of Anti-CD3 Targeted Therapy - Screening for Islet Autoantibodies in Children and Adolescents to Prevent/Delay T1D
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Experts in the immunopathology of type 1 diabetes review data showing that clinical presentation is preceded by an asymptomatic phase, characterized by the presence of one or more islet autoantibodies. Screening children for islet autoantibodies during the two preclinical stages can identify those with multiple autoantibodies and high-risk antibody phenotypes who may be candidates for preventive interventions before developing dysglycemia or the clinical onset of type 1 diabetes.


  • Disclosure of Conflicts of Interest

    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

    The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

    Name of Faculty or Presenter

    Reported Financial Relationship

    Kevan Herold

    Consultant/Independent Contractor: Biogen, Provention Bio, Viela Pharma

    Andrea Steck

    Contracted Research: Helmsley Foundation, Jansse, JDRF, Provention Bio

    Anette-Gabriele Ziegler

    Receipt of Intellectual Property Rights/Patent Holder: PLA17A05; International patient application no: WO2019/002364: “Method for determining the risk to develop type 1 diabetes” by Hemlholyz Zentrum Munchen Deutsches Forschungszentrum fur Gesundheit und Umwelt (GmbH). Anette Ziegler is listed as one of the inventors

    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    Name of Planner or Manager

    Reported Financial Relationship

    PIM Planners and Managers

    Nothing to disclose

    Raquel Da Rosa

    Nothing to disclose

    Joanne Jablonski

    Nothing to disclose

  • Target Audience

    This activity is intended for pediatricians, endocrinologists and primary care physicians engaged in the care of patients with Type 1 diabetes or with the risk of developing T1D.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    1. Apply a staging classification system that can identify children with asymptomatic type 1 diabetes before they develop clinical disease.  
    2. Screen children at high risk for type 1 diabetes for islet autoantibodies and consider preventive interventions for those with multiple autoantibodies and high-risk antibody phenotypes before clinical disease supervenes.
  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and HealthmattersCME.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Physician Continuing Medical Education
    The Postgraduate Institute for Medicine designates this enduring material for a maximum of .50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    This activity is supported by an independent educational grant from Provention Bio.

  • Postgraduate Institute for Medicine (PIM) Information

    For information about the accreditation of this program, please contact PIM at inquiries@pimed.com or 800-423-3576.

  • Term of Offering

    This activity was released on July 7, 2021 and is valid for one year. Requests for credit must be made no later than July 7, 2022. Estimated time to complete: 30 minutes

  • Fee Information & Refund/Cancellation Policy

    There is no fee for this educational activity.

  • Disclaimer

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.   The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Experts in the immunopathology of type 1 diabetes review data showing that clinical presentation is preceded by an asymptomatic phase, characterized by the presence of one or more islet autoantibodies. Screening children for islet autoantibodies during the two preclinical stages can identify those with multiple autoantibodies and high-risk antibody phenotypes who may be candidates for preventive interventions before developing dysglycemia or the clinical onset of type 1 diabetes.


  • Disclosure of Conflicts of Interest

    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

    The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

    Name of Faculty or Presenter

    Reported Financial Relationship

    Kevan Herold

    Consultant/Independent Contractor: Biogen, Provention Bio, Viela Pharma

    Andrea Steck

    Contracted Research: Helmsley Foundation, Jansse, JDRF, Provention Bio

    Anette-Gabriele Ziegler

    Receipt of Intellectual Property Rights/Patent Holder: PLA17A05; International patient application no: WO2019/002364: “Method for determining the risk to develop type 1 diabetes” by Hemlholyz Zentrum Munchen Deutsches Forschungszentrum fur Gesundheit und Umwelt (GmbH). Anette Ziegler is listed as one of the inventors

    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    Name of Planner or Manager

    Reported Financial Relationship

    PIM Planners and Managers

    Nothing to disclose

    Raquel Da Rosa

    Nothing to disclose

    Joanne Jablonski

    Nothing to disclose

  • Target Audience

    This activity is intended for pediatricians, endocrinologists and primary care physicians engaged in the care of patients with Type 1 diabetes or with the risk of developing T1D.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    1. Apply a staging classification system that can identify children with asymptomatic type 1 diabetes before they develop clinical disease.  
    2. Screen children at high risk for type 1 diabetes for islet autoantibodies and consider preventive interventions for those with multiple autoantibodies and high-risk antibody phenotypes before clinical disease supervenes.
  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and HealthmattersCME.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Physician Continuing Medical Education
    The Postgraduate Institute for Medicine designates this enduring material for a maximum of .50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    This activity is supported by an independent educational grant from Provention Bio.

  • Postgraduate Institute for Medicine (PIM) Information

    For information about the accreditation of this program, please contact PIM at inquiries@pimed.com or 800-423-3576.

  • Term of Offering

    This activity was released on July 7, 2021 and is valid for one year. Requests for credit must be made no later than July 7, 2022. Estimated time to complete: 30 minutes

  • Fee Information & Refund/Cancellation Policy

    There is no fee for this educational activity.

  • Disclaimer

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.   The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Programs 7/27/21